481 related articles for article (PubMed ID: 16054372)
1. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
2. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
3. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
5. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
6. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
7. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(6):2180-93. PubMed ID: 14632470
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
10. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
12. Computational design of new cyclic urea inhibitors for improved binding of HIV-1 aspartic protease.
Kotamarthi B; Bonin I; Benedetti F; Miertus S
Biochem Biophys Res Commun; 2000 Feb; 268(2):384-9. PubMed ID: 10679213
[TBL] [Abstract][Full Text] [Related]
13. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
[TBL] [Abstract][Full Text] [Related]
17. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
18. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
Sperka T; Pitlik J; Bagossi P; Tözsér J
Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
[TBL] [Abstract][Full Text] [Related]
19. Predicting drug-resistant mutations of HIV protease.
Ishikita H; Warshel A
Angew Chem Int Ed Engl; 2008; 47(4):697-700. PubMed ID: 18058968
[No Abstract] [Full Text] [Related]
20. Anti-HIV activity of HEPT, TIBO, and cyclic urea derivatives: structure-property studies, focused combinatorial library generation, and hits selection using substructural molecular fragments method.
Solov'ev VP; Varnek A
J Chem Inf Comput Sci; 2003; 43(5):1703-19. PubMed ID: 14502505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
